Cargando…

Anticancer drug R&D landscape in China

Detalles Bibliográficos
Autores principales:	Zhao, Shen, Zhao, Hongyun, Lv, Cheng, Gong, Jifang, Zhang, Jian, Fang, Wenfeng, Li, Jin, Hu, Xichun, Ba, Yi, Xu, Binghe, Zhang, Yanqiao, Fan, Yun, Li, Kunyan, Chen, Xiaoyuan, Yang, Zhimin, Shen, Lin, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218822/ https://www.ncbi.nlm.nih.gov/pubmed/32404176 http://dx.doi.org/10.1186/s13045-020-00877-3

Ejemplares similares

Anticancer drug R&D of gastrointestinal cancer in China: Current landscape and challenges
por: Shen, Lin
Publicado: (2022)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China
por: Zhang, Zhonghan, et al.
Publicado: (2021)

Traumatic oculomotor nerve palsy treated with transnasal endoscopic decompression through the optic strut
por: Wang, Anqi, et al.
Publicado: (2023)

Evolution of drug regulations and regulatory innovation for anticancer drugs in China
por: Liu, Yang, et al.
Publicado: (2022)

Impact on long-term survival of the number of lymph nodes resected in patients with pT1N0 gastric cancer after R0 resection: A multicenter study in China
por: Zhao, Jiuda, et al.
Publicado: (2016)

Identification of Immune Cell Infiltration Landscape and Their Prognostic Significance in Uveal Melanoma
por: Zhao, Han, et al.
Publicado: (2021)

Evolving drug regulatory landscape in China: A clinical pharmacology perspective
por: Tang, Weifeng, et al.
Publicado: (2021)

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
por: Zhao, Shen, et al.
Publicado: (2020)

Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China
por: Zhang, Qingyuan, et al.
Publicado: (2016)

Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2021)

Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer
por: Jin, Juan, et al.
Publicado: (2023)

The genus Apterygothrips Priesner (Thysanoptera, Phlaeothripinae, Haplothripini) from China, with one new species
por: Dang, Lihong, et al.
Publicado: (2022)

SLC26A4 gene polymorphism and late-onset Alzheimer's disease in a Han Chinese population from Qingdao, China☆
por: Zhang, Jifang, et al.
Publicado: (2013)

Methicillin-Resistant Staphylococcus aureus Carriage among Students at a Historically Black University: A Case Study
por: Shen, Hua, et al.
Publicado: (2013)

The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification
por: Yang, Yefan, et al.
Publicado: (2022)

Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites
por: Kou, Furong, et al.
Publicado: (2021)

Gene and cell therapies in China: booming landscape under dual-track regulation
por: Yin, Chen, et al.
Publicado: (2022)

Effect of Landscape Pattern on Insect Species Density within Urban Green Spaces in Beijing, China
por: Su, Zhimin, et al.
Publicado: (2015)

Impact of prior cancer history on the overall survival of younger patients with lung cancer
por: Liu, Jiaqing, et al.
Publicado: (2020)

Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case Report
por: Shen, Gang, et al.
Publicado: (2021)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Zhonghan, et al.
Publicado: (2020)

Design and synthesis of novel oridonin analogues as potent anticancer agents
por: Shen, Qing-Kun, et al.
Publicado: (2018)

Evolution of Early-Phase Anticancer Drug Investigations in China
por: Wang, Shuhang, et al.
Publicado: (2022)

The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma
por: Hong, Shaodong, et al.
Publicado: (2019)

Gender differences in self-view and desired salaries: A study on online recruitment website users in China
por: Zhang, Xiaoqi, et al.
Publicado: (2019)

To Float or Not to Float? Internal Migration of Skilled Laborers in China
por: Zheng, Yanqiao, et al.
Publicado: (2020)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Zhonghan, et al.
Publicado: (2019)

The Effectiveness of RECIST on Survival in Patients with NSCLC Receiving Chemotherapy with or without Target Agents as First-Line Treatment
por: Zhou, Ting, et al.
Publicado: (2015)

Accessibility of essential anticancer medicines for children in the Sichuan Province of China
por: Chen, Zhe, et al.
Publicado: (2022)

Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
por: Li, Junjie, et al.
Publicado: (2018)

The education-chasing labor rush in China identified by a heterogeneous migration-network game
por: Zhang, Xiaoqi, et al.
Publicado: (2020)

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
por: Chen, Yang, et al.
Publicado: (2021)

Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer
por: Li, Yilin, et al.
Publicado: (2016)

Synergistic anticancer effects of nanocarrier loaded with berberine and miR-122
por: Li, Lei, et al.
Publicado: (2018)

Naringenin Decreases Invasiveness and Metastasis by Inhibiting TGF-β-Induced Epithelial to Mesenchymal Transition in Pancreatic Cancer Cells
por: Lou, Changjie, et al.
Publicado: (2012)

The new Good Clinical Practice-2020 in China: Views from ethical perspective
por: Yang, Feng, et al.
Publicado: (2021)

Editorial: RNA recognition landscapes and anticancer drug targeting
por: Salvati, Erica, et al.
Publicado: (2023)

Integrated multi-omics analysis reveals miR-20a as a regulator for metabolic colorectal cancer
por: Song, Kai, et al.
Publicado: (2022)

Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway
por: Li, Ting, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_umk0p4nh1grd488gihej4bn261